Accelerating Research and Development With BioPharma Diagnostics

From Answers from the Lab by Mayo Clinic Laboratories

December 4, 2025 · 24 min · Episode 373

About this episode

This episode discusses PAMA reform, the first death from alpha-gal syndrome, and the role of biopharma diagnostics in advancing research and development.

Published Dec. 4, 2025 In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D. , president and CEO of Mayo Clinic Laboratories, to discuss Protecting Access to Medicare Act (PAMA) reform and the first reported death from alpha-gal syndrome. Later, Dr. Pritt welcomes Chris Garcia, M.D. , Mayo Clinic Laboratories’ chief digital innovation officer and medical director of BioPharma Diagnostics, to explore how biopharma diagnostics advance research and development. PAMA reform update (00:33): Get the latest on where reform to PAMA stands following the federal government’s reopening. Alpha-gal syndrome case (03:22) : Learn about the first known death from alpha-gal syndrome and diagnostic testing for this tick-bite-triggered red meat allergy. Biopharma’s role in research and development (07:52) : Discover how biopharma diagnostics fuel innovation and how digital tools are expanding its future impact. Note: Information in this post was accurate at the time of its posting. Resources BioPharma Diagnostics: Connecting pharma and biotech Tick-borne disease: An expanding…

People in this episode

Host: Bobbi Pritt, M.D.

Guests: William Morice II, M.D., Ph.D., Chris Garcia, M.D.

Topics covered

PAMA reform
alpha-gal syndrome
biopharma diagnostics
research and development
digital innovation

Keywords

PAMA reform
alpha-gal syndrome
biopharma diagnostics
research
development
digital tools
tick-borne disease

Mentioned in this episode

Organizations: Mayo Clinic Laboratories

Products: biopharma diagnostics